RTW Investments LP recently announced the acquisition of new stake in Immunic Inc (NASDAQ:IMUX). The institutional investor has increased its shareholding in the Healthcare company by 0.95% to 4.34 million shares with purchase of 40796.0 shares. This fresh investment now brings its stake to 9.60% valued currently at $5.16 million. In addition, Gratus Capital LLC raised its holdings by 7662.0 to 1.69 million shares. And Acadian Asset Management LLC has lifted its position by 26.78% or 0.16 million shares – to 0.76 million shares.
With over 18.32 million Immunic Inc (IMUX) shares trading Friday and a closing price of $1.39 on the day, the dollar volume was approximately $25.46 million. The shares have shown a negative half year performance of -45.91% and its price on 01/05/24 lost nearly -2.80%. Currently, there are 39.31M common shares owned by the public and among those 38.39M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 1 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 1 of these insider trades were purchases, accounting for 5,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Immunic Inc are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market ETF owns 1.14 million shares of the company’s stock, all valued at over $1.36 million. Fidelity Extended Market Index Fu bought 23378.0 shares to bring its total holdings to over 0.16 million shares at a value of $0.19 million. Fidelity Extended Market Index Fu now owns shares totaling to 0.36% of the shares outstanding.
Shares of Immunic Inc (NASDAQ: IMUX) opened at $1.70, up $0.27 from a prior closing price of $1.43. However, the script later moved the day high at 1.7248, down -2.80%. The company’s stock has a 5-day price change of -10.32% and 0.00% over the past three months. It has a 12-month low price of $0.95 and touched a high of $3.17 over the same period. IMUX has an average intraday trading volume of 828.32K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.94%, 15.01%, and -13.17% respectively.
Institutional ownership of Immunic Inc (NASDAQ: IMUX) shares accounts for 43.17% of the company’s 39.31M shares outstanding. Mutual fund holders own 31.60%, while other institutional holders and individual stakeholders account for 5.26% and 2.43% respectively.
It has a market capitalization of $62.76M and a beta (3y monthly) value of 2.05. The earnings-per-share (ttm) stands at -$3.26. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.96% over the week and 10.04% over the month.
Analysts forecast that Immunic Inc (IMUX) will achieve an EPS of -$0.5 for the current quarter, -$0.48 for the next quarter and -$1.85 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.53 while analysts give the company a high EPS estimate of -$0.43. Comparatively, EPS for the current quarter was -$1.62 a year ago. Earnings per share for the fiscal year are expected to increase by 43.19%, and 14.90% over the next financial year. EPS should shrink at an annualized rate of 15.50% over the next five years, compared to 40.88% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Immunic Inc (IMUX) as a “Strong Buy” at a consensus score of 1.50. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 1 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the IMUX, a number of firms have released research notes about the stock. SVB Leerink stated their Mkt Perform rating for the stock in a research note on October 21, 2022, with the firm’s price target at $5.
